The DOI matches its Crossref record.
Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States
Abstract
Insulin resistance and the metabolic syndrome are associated with fasting and postprandial dyslipidemia. This involves the hepatic and intestinal overproduction of very low density lipoproteins (VLDL) and chylomicron particles, respectively, which give rise to atherogenic remnants upon lipolysis in the circulation. Recently, the insulin secretagogue glucagon-like peptide-1 (GLP-1) has received attention not only as an anti-diabetic therapy for regulating glycaemia, but also as a regulator of lipid and lipoprotein metabolism. In fact, agents that raise endogenous bioactive levels of GLP-1 (dipeptidyl peptidase 4 inhibitors) and agents that directly stimulate GLP-1 receptors (GLP-1 receptor agonists) have been assessed in both preclinical and clinical trials for their ability to modulate plasma lipid parameters. Here we describe current evidence supporting a role for GLP-1 in preventing elevated intestinal chylomicron output and postprandial hypertriglyceridemia--an independent predictor of cardiovascular risk. Furthermore, we examine a role for GLP-1 in regulating fasting hepatic VLDL production and hindering the development of a potentially devastating comorbidity, hepatic steatosis. Possible mechanisms of action of GLP-1 are discussed including a reduction in intestinal absorption of dietary lipid and enhanced hepatic fatty acid oxidation or autophagy. Finally, we discuss the current controversy over whether these effects could occur via direct receptor stimulation or alternative, indirect pathways. We conclude that GLP- 1-based therapies appear promising in the management of diabetic dyslipidemia, and further studies are warranted to elucidate their mechanisms of action in both the intestine and liver.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They reduce the production and secretion of intestinal chylomicrons with beneficial effects on plasma levels of total cholesterol, low-density lipoprotein (LDL) and triglycerides [39];”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [39]
Citations
Cited by
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
The Canadian laboratory initiative on pediatric reference intervals: A CALIPER white paper
Adeli, K., Higgins, V., Trajcevski, K., & White-Al Habeeb, N. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1379945 · Cited by 303
Self-citationGLP-1 receptor agonists and kidney protection
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S. (2019) · Medicina · doi:10.3390/medicina55060233 · Cited by 173
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
The Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism
Yu, Y., Raka, F., & Adeli, K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122227 · Cited by 160
Self-citation
Metadata
- Authors
- Farr, S., Taher, J., & Adeli, K.
- Affiliations
- Hospital for Sick Children (CA)
- Venue
- Cardiovascular & Hematological Disorders-Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-08-31
- Volume
- 14
- Issue
- 2
- Pages
- 126-136
- ISSN
- 1568-0061 (ISSN-L)
- 1871-529X
- OpenAlex
- W2133027387
- Cited by
- 61
- References
- 0
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 7 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 8 · 2017: 6 · 2016: 2 · 2015: 1 · 2014: 1
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cardiovascular & Haematological Disorders - Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- glucagon-like peptide-1, lipid metabolism, lipoprotein metabolism, postprandial hypertriglyceridemia, hepatic steatosis, DPP-4 inhibitors, GLP-1 receptor agonists, insulin resistance, metabolic syndrome, hepatic fatty acid oxidation, autophagy, dietary fat absorption, cardiovascular risk
- MeSH terms
- Animals, Cardiovascular Diseases, Chylomicrons, Fasting, Fatty Liver, Humans, Insulin Resistance, Intestinal Mucosa, Lipoproteins, Liver, Risk Factors, Triglycerides, Postprandial Period, Dyslipidemias, Lipid Metabolism, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States. https://app.cochat.ai/papers/10.2174/1871529x14666140505125300
- The paper
- Farr, S., Taher, J., & Adeli, K. (2014). Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States. Cardiovascular & Hematological Disorders-Drug Targets. https://doi.org/10.2174/1871529x14666140505125300
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.